| 1 |
2020 |
A risk signature-based on metastasis-associated genes to predict survival of patients with osteosarcoma. |
--- |
| 2 |
2020 |
Acquisition of stem associated-features on metastatic osteosarcoma cells and their functional effects on mesenchymal stem cells. |
MSCs |
| 3 |
2020 |
Biology and pathogenesis of human osteosarcoma. |
--- |
| 4 |
2020 |
Chlorogenic acid activates ERK1/2 and inhibits proliferation of osteosarcoma cells. |
CGA |
| 5 |
2020 |
Cold atmospheric plasma inhibits the growth of osteosarcoma cells by inducing apoptosis, independent of the device used. |
CAP |
| 6 |
2020 |
Cold Plasma-Treated Ringer's Saline: A Weapon to Target Osteosarcoma. |
PAR |
| 7 |
2020 |
Delineation of hypoxia-induced proteome shifts in osteosarcoma cells with different metastatic propensities. |
--- |
| 8 |
2020 |
Dioscin inhibits the growth of human osteosarcoma by inducing G2/M-phase arrest, apoptosis, and GSDME-dependent cell death in vitro and in vivo. |
GSDME, PCD |
| 9 |
2020 |
Downregulation of lncRNA SNHG12 reversed IGF1R-induced osteosarcoma metastasis and proliferation by targeting miR-195-5p. |
IGF1R, lncSNHG12 |
| 10 |
2020 |
Expression of the double-stranded RNA-dependent kinase PKR influences osteosarcoma attachment independent growth, migration, and invasion. |
DN, PKR |
| 11 |
2020 |
Functional variant of IL33 is associated with survival of osteosarcoma patients. |
--- |
| 12 |
2020 |
G721-0282 inhibits cell growth and induces apoptosis in human osteosarcoma through down-regulation of the STAT3 pathway. |
Chi3L1, MAPKs |
| 13 |
2020 |
Gankyrin promotes osteosarcoma tumorigenesis by forming a positive feedback loop with YAP. |
YAP |
| 14 |
2020 |
Growth hormone receptor promotes osteosarcoma cell growth and metastases. |
GHR |
| 15 |
2020 |
HSP90 regulates osteosarcoma cell apoptosis by targeting the p53/TCF-1-mediated transcriptional network. |
Hsp90 |
| 16 |
2020 |
Identification of osteosarcoma driver genes using a network method. |
--- |
| 17 |
2020 |
Interstitial serum albumin empowers osteosarcoma cells with FAIM2 transcription to obtain viability via dedifferentiation. |
FAIM2 |
| 18 |
2020 |
Knockdown of Ski decreases osteosarcoma cell proliferation and migration by suppressing the PI3K/Akt signaling pathway. |
--- |
| 19 |
2020 |
LINC00324 accelerates the proliferation and migration of osteosarcoma through regulating WDR66. |
lncRNA, WDR66 |
| 20 |
2020 |
LINC00657 activates PD-L1 to promote osteosarcoma metastasis via miR-106a. |
PD-L1, RT-qPCR |
| 21 |
2020 |
LncRNA CRNDE is activated by SP1 and promotes osteosarcoma proliferation, invasion, and epithelial-mesenchymal transition via Wnt/beta-catenin signaling pathway. |
CRNDE, lncRNAs |
| 22 |
2020 |
LncRNA DANCR silence inhibits SOX5-medicated progression and autophagy in osteosarcoma via regulating miR-216a-5p. |
DANCR, miR-216a-5p, qRT-PCR |
| 23 |
2020 |
LncRNA FTX inhibition restrains osteosarcoma proliferation and migration via modulating miR-320a/TXNRD1. |
HCC, LncRNAs, RCC |
| 24 |
2020 |
LncRNA PCAT6 promotes tumor progression in osteosarcoma via activation of TGF-beta pathway by sponging miR-185-5p. |
lncRNAs |
| 25 |
2020 |
LncRNA RP11-361F15.2 promotes osteosarcoma tumorigenesis by inhibiting M2-Like polarization of tumor-associated macrophages of CPEB4. |
ceRNA, CPEB4, lncRNAs, TAMs |
| 26 |
2020 |
LncRNA SPRY4‑IT1 promotes progression of osteosarcoma by regulating ZEB1 and ZEB2 expression through sponging of miR‑101 activity. |
lnc, ZEBs |
| 27 |
2020 |
LncRNA TMPO-AS1 serves as a ceRNA to promote osteosarcoma tumorigenesis by regulating miR-199a-5p/WNT7B axis. |
lncRNAs |
| 28 |
2020 |
Long non-coding RNA CDKN2B-AS1 promotes osteosarcoma by increasing the expression of MAP3K3 via sponging miR-4458. |
lncRNA |
| 29 |
2020 |
Long noncoding RNA LEF1-AS1 binds with HNRNPL to boost the proliferation, migration, and invasion in osteosarcoma by enhancing the mRNA stability of LEF1. |
--- |
| 30 |
2020 |
MicroRNA-1296-5p suppresses the proliferation, migration, and invasion of human osteosarcoma cells by targeting NOTCH2. |
NOTCH2 |
| 31 |
2020 |
MicroRNA-150 functions as a tumor suppressor and sensitizes osteosarcoma to doxorubicin-induced apoptosis by targeting RUNX2. |
miR-150, miRNAs |
| 32 |
2020 |
miR-139-mediated NOTCH1 regulation is crucial for the inhibition of osteosarcoma progression caused by resveratrol. |
--- |
| 33 |
2020 |
Multifunctional bone cement for synergistic magnetic hyperthermia ablation and chemotherapy of osteosarcoma. |
FDA, MH |
| 34 |
2020 |
Nanomedicine in osteosarcoma therapy: micelleplexes for delivery of nucleic acids and drugs for osteosarcoma-targeted therapy. |
--- |
| 35 |
2020 |
Novel classifiers with clinical laboratory parameters for early detection of osteosarcoma. |
ALP, ROC |
| 36 |
2020 |
Osteosarcoma-initiating cells show high aerobic glycolysis and attenuation of oxidative phosphorylation mediated by LIN28B. |
OSHIGH, SIC |
| 37 |
2020 |
Outcomes for pediatric patients with osteosarcoma treated with palliative radiotherapy. |
EQD2, RT |
| 38 |
2020 |
Paeonol antagonizes oncogenesis of osteosarcoma by inhibiting the function of TLR4/MAPK/NF-kappaB pathway. |
Pae |
| 39 |
2020 |
PAXX is a novel target to overcome resistance to doxorubicin and cisplatin in osteosarcoma. |
NHEJ |
| 40 |
2020 |
Positive feedback loop SP1/MIR17HG/miR-130a-3p promotes osteosarcoma proliferation and cisplatin resistance. |
lncRNAs |
| 41 |
2020 |
Potential regulatory role of lncRNA-miRNA-mRNA axis in osteosarcoma. |
lncRNAs, miRNAs |
| 42 |
2020 |
Reduction-responsive polypeptide nanomedicines significantly inhibit progression of orthotopic osteosarcoma. |
DOX |
| 43 |
2020 |
Signatures of circulating microRNA in four sarcoma subtypes. |
ES, GIST, ROC AUC, SS |
| 44 |
2020 |
The microRNA‑708‑5p/ZEB1/EMT axis mediates the metastatic potential of osteosarcoma. |
DEmiRNAs, EMT, MAP3K3, SEMA4C, ZEB1 |
| 45 |
2019 |
A comparison of risk factors for metastasis at diagnosis in humans and dogs with osteosarcoma. |
--- |
| 46 |
2019 |
A four serum-miRNA panel serves as a potential diagnostic biomarker of osteosarcoma. |
AUC, miRNAs, ROC |
| 47 |
2019 |
A global transcriptomic pipeline decoding core network of genes involved in stages leading to acquisition of drug-resistance to cisplatin in osteosarcoma cells. |
--- |
| 48 |
2019 |
A humanized bone microenvironment uncovers HIF2 alpha as a latent marker for osteosarcoma. |
hTEBOs, rhBMP-7 |
| 49 |
2019 |
A newly synthesized oleanolic acid derivative inhibits the growth of osteosarcoma cells in vitro and in vivo by decreasing c-MYC-dependent glycolysis. |
CDDO-NFM |
| 50 |
2019 |
A Novel lncRNA MYOSLID/miR-1286/RAB13 Axis Plays a Critical Role in Osteosarcoma Progression. |
lncRNA, RIP |
| 51 |
2019 |
Activation of CXCL6/CXCR1/2 Axis Promotes the Growth and Metastasis of Osteosarcoma Cells in vitro and in vivo. |
CXCL6, EMT |
| 52 |
2019 |
Activation of dynamin-related protein 1 - dependent mitochondria fragmentation and suppression of osteosarcoma by cryptotanshinone. |
Bax, CPT, Drp1 |
| 53 |
2019 |
ACTN4 Promotes the Proliferation, Migration, Metastasis of Osteosarcoma and Enhances its Invasive Ability through the NF-kappaB Pathway. |
ACTN4, HE |
| 54 |
2019 |
Adjuvant Biophysical Therapies in Osteosarcoma. |
HIFU, HT, LIPUS, SDT, PDT |
| 55 |
2019 |
Advanced development of ErbB family-targeted therapies in osteosarcoma treatment. |
--- |
| 56 |
2019 |
alpha,gamma-Diketocarboxylic Acids and Their Esters Act as Carbonic Anhydrase IX and XII Selective Inhibitors. |
CA |
| 57 |
2019 |
Analyzing the Interactions of mRNAs and ncRNAs to Predict Competing Endogenous RNA Networks in Osteosarcoma Chemo-Resistance. |
ceRNA, circRNA, GO, KEGG, lncRNA, miRNA, ncRNAs, RIP |
| 58 |
2019 |
Angiogenesis Process in Osteosarcoma: An Updated Perspective of Pathophysiology and Therapeutics. |
--- |
| 59 |
2019 |
Angiopoietin-like protein 2 is an important facilitator of tumor proliferation, metastasis, angiogenesis and glycolysis in osteosarcoma. |
Angptl2 |
| 60 |
2019 |
Anoikis resistant mediated by FASN promoted growth and metastasis of osteosarcoma. |
AR, FASN |
| 61 |
2019 |
Anti-tumor efficacy of phellamurin in osteosarcoma cells: Involvement of the PI3K/AKT/mTOR pathway. |
mTOR, P. amurense, Phe, PI3K |
| 62 |
2019 |
Anticancer Potential of Oleuropein, the Polyphenol of Olive Oil, With 2-Methoxyestradiol, Separately or in Combination, in Human Osteosarcoma Cells. |
2-ME |
| 63 |
2019 |
Antimetastatic effects of calycosin on osteosarcoma and the underlying mechanism. |
CC, ECT2, IkappaBalpha, MMP2, PCNA |
| 64 |
2019 |
Apiosporamide, A 4-hydroxy-2-pyridone Alkaloid, Induces Apoptosis Via PI3K/Akt Signaling Pathway In Osteosarcoma Cells. |
--- |
| 65 |
2019 |
Association between PTEN and clinical-pathological features of osteosarcoma. |
CBM, CIs, CNKI, OR, PTEN |
| 66 |
2019 |
ATF4 destabilizes RET through nonclassical GRP78 inhibition to enhance chemosensitivity to bortezomib in human osteosarcoma. |
ATF4, BTZ, FISH, OS/BTZ |
| 67 |
2019 |
ATF6alpha Activation Enhances Survival against Chemotherapy and Serves as a Prognostic Indicator in Osteosarcoma. |
ER, PDI |
| 68 |
2019 |
Attenuation of STAT3 Phosphorylation Promotes Apoptosis and Chemosensitivity in Human Osteosarcoma Induced by Raddeanin A. |
IL-6, RA |
| 69 |
2019 |
Atypical "Sclerosing" Osteoblastic Neoplasm: A Tumor of Intermediate Biological Potential Between Usual Osteoblastoma and Conventional Osteosarcoma. |
OB |
| 70 |
2019 |
Avasimibe inhibits tumor growth by targeting FoxM1-AKR1C1 in osteosarcoma. |
--- |
| 71 |
2019 |
Baicalin inhibits growth and induces apoptosis of human osteosarcoma cells by suppressing the AKT pathway. |
--- |
| 72 |
2019 |
Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo. |
CCK-8, PD-L1, RT-qPCR |
| 73 |
2019 |
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations. |
EW, PDX |
| 74 |
2019 |
Bone transport using the Ilizarov method for osteosarcoma patients with tumor resection and neoadjuvant chemotherapy. |
EFI |
| 75 |
2019 |
BTF3 Silencing Inhibits the Proliferation of Osteosarcoma Cells. |
BTF3, LV-BTF3-shRNA, MTT |
| 76 |
2019 |
C-terminal of E1A binding protein 2 promotes the malignancy of osteosarcoma cells via JAK1/Stat3 signaling. |
--- |
| 77 |
2019 |
Canine osteosarcoma genome sequencing identifies recurrent mutations in DMD and the histone methyltransferase gene SETD2. |
WES |
| 78 |
2019 |
Canine osteosarcoma genome sequencing identifies recurrent mutations in DMD and the histone methyltransferase gene SETD2. |
WES |
| 79 |
2019 |
Carboxypeptidase E-DeltaN promotes migration, invasiveness, and epithelial-mesenchymal transition of human osteosarcoma cells via the Wnt-beta-catenin pathway. |
CPE, EMT, siRNA |
| 80 |
2019 |
CDKN2B-AS1 Exerts Oncogenic Role in Osteosarcoma by Promoting Cell Proliferation and Epithelial to Mesenchymal Transition. |
CDKN2B-AS1, EMT, lncRNAs |
| 81 |
2019 |
Characterization of five newly derived canine osteosarcoma cell lines. |
--- |
| 82 |
2019 |
Chinese Herbal Medicine for Osteosarcoma in the Mouse: A Systematic Review and Meta-Analysis. |
CBM, CHM, Cl, CNKI, MD |
| 83 |
2019 |
CircSAMD4A accelerates cell proliferation of osteosarcoma by sponging miR-1244 and regulating MDM2 mRNA expression. |
circRNAs |
| 84 |
2019 |
Circular RNA circTADA2A promotes osteosarcoma progression and metastasis by sponging miR-203a-3p and regulating CREB3 expression. |
circRNAs, FISH, RIP |
| 85 |
2019 |
Circular RNA circ_0102049 promotes cell progression as ceRNA to target MDM2 via sponging miR-1304-5p in osteosarcoma. |
CCK-8, ceRNA, circRNA, qRT-RCR |
| 86 |
2019 |
Circ_0001658 promotes the proliferation and metastasis of osteosarcoma cells via regulating miR-382-5p/YB-1 axis. |
circRNA, miRNA, YB-1 |
| 87 |
2019 |
CLDN10 promotes a malignant phenotype of osteosarcoma cells via JAK1/Stat1 signaling. |
CCK-8, CLDNs, JAK1, RNAi, STAT1, TJ |
| 88 |
2019 |
Clinical case report of patients with osteosarcoma and anticancer benefit of calycosin against human osteosarcoma cells. |
Bcl-2, CC, LD, miR-223, PARP |
| 89 |
2019 |
Clinical importance of S100A9 in osteosarcoma development and as a diagnostic marker and therapeutic target. |
qRT-PCR |
| 90 |
2019 |
Clinicopathologic Features and Genetic Alterations of a Primary Osteosarcoma of the Uterine Corpus. |
MED12 |
| 91 |
2019 |
Co-Expression Network Analysis Identified Gene Signatures in Osteosarcoma as a Predictive Tool for Lung Metastasis and Survival. |
GEO, LASSO, WGCNA |
| 92 |
2019 |
Concurrent Osteosarcoma Theranostic Strategy Using Contrast-Enhanced Ultrasound and Drug-Loaded Bubbles. |
US |
| 93 |
2019 |
cPLA2a correlates with metastasis and poor prognosis of osteosarcoma by facilitating epithelial-mesenchymal transition. |
cPLA2, EMT |
| 94 |
2019 |
Craniomaxillofacial osteosarcoma - The role of surgical margins. |
CMF |
| 95 |
2019 |
CRIF1-CDK2 Interface Inhibitors: An Unprecedented Strategy for Modulation of Cell Radiosensitivity. |
BMSC, CDKs, CRIF1, IR |
| 96 |
2019 |
Cross-Species Gene Expression Analysis Reveals Gene Modules Implicated in Human Osteosarcoma. |
CD86, PPI, WGCNA |
| 97 |
2019 |
Cross-species genomics identifies DLG2 as a tumor suppressor in osteosarcoma. |
DLG2 |
| 98 |
2019 |
Crosstalk between Hh and Wnt signaling promotes osteosarcoma progression. |
--- |
| 99 |
2019 |
CSN5 controls the growth of osteosarcoma via modulating the EGFR/PI3K/Akt axis. |
COP9 |
| 100 |
2019 |
Curcumin inhibits the proliferation and invasion of MG-63 cells through inactivation of the p-JAK2/p-STAT3 pathway. |
--- |
A Search Service for Abbreviation / Long Form
